57 results about "VCAM-1" patented technology

A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers is provided, as well as enriched populations of mesenchymal precursor cells and compositions comprising the cells. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.

A method for the inhibition of the binding of .alpha..sub.4.beta..sub.1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which .alpha..sub.4.beta..sub.1 is involved.

A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.

A composition, method and kit comprising a compound for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin and other therapeutic compounds for the control or prevention of diseases states in which α4β1 is involved.

This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-α) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions. The invention relates to inhibition of the expression of intercellular adhesion molecule 1 (ICAM-1), vascular-cell adhesion molecule 1 (VCAM-1), and E-Selectin by the said compositions. The said compositions may optionally contain at least one anti-inflammatory agent or can be used in combination with at least one anti-inflammatory agent.

A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1 is involved.

Compositions and methods for detecting various disorders with targeted microbubbles are disclosed. Specifically, microbubbles comprising glycoprotein Ib (GPIb), ligands for VCAM-1, and ligands for P-selectin such as PSGL-1 are disclosed. Also disclosed are methods for using targeted microbubbles to detect cardiovascular disease comprising administering the disclosed microbubbles to a subject and detecting the microbubbles in the vasculature using ultrasound.

The present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. In particular, methimazole derivatives and tautomeric cyclic thiones have the ability to inhibit the adhesion and the migration of leukocytes. In addition to being active anti-inflammatories, the methimazole derivatives and tautomeric cyclic thiones and their physiologically tolerable salts, derivatives and prodrugs are generally suitable for the treatment (i.e., for the therapy and prophylaxis) of diseases that are based on the interaction between VCAM-1 and its ligands or can be influenced by an inhibition of this interaction. In particular, the methimazole derivatives and tautomeric cyclic thiones are suitable for the treatment of diseases that are caused at least partly by an undesired extent of leukocyte adhesion and / or leukocyte migration or are connected therewith, and for whose prevention, alleviation or cure the adhesion and / or migration of leukocytes should be decreased.

The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, β3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle α-actin, nestin, hepatocyte growth factor, stromal derived factor-1α and H1x homeobox transcriptional factor.

The invention discloses a method for detecting the angiogenesis promoting capacity of an MSC through VCAM-1. The method is characterized in that a new purpose of known protein VCAM-1 is found, the protein expression of VCAM-1 is detected through an ELISA, the total protein content is measured through a Bradford method, and the angiogenesis promoting capacity of the cell is reflected through the protein content of VCAM-1 in every 1 g of total protein. The angiogenesis promoting capacity of the MSC can be quantified through the method.

The invention belongs to a preparation method and application of a bovine VCAM-1 polyclonal antibody. The method comprises the following steps of (1) RNA (ribonucleic acid) extraction; (2) reverse transcription PCR (polymerase chain reaction); (3) primer design and synthesis; (4) gene fragment amplification; (5) gene clone; (6) prokaryotic expression vector building; (7) expression and identification of DNA (deoxyribonucleic acid) recombinant plasmid in escherichia coli; (8) recombinant protein purification; (9) protein blotting; (10) recombinant protein dialysis and concentration determination; (11) immunizing antigen preparation; (12) immunizing and blood collection; (13) serum separation. The polyclonal antibody provided by the invention can be used for identifying the bovine recombinant VCAM-1 protein and natural recombinant VCAM-1 protein; the valence of the VCAM-1 polyclonal antibody is high; the specificity is high. The antibody particularly aims at the bovine natural VCAM-1 protein.

This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3- methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1 ,2-b]furan-2-one (7- Hydroxy-4,1 1 (13)-eudesmadien-12,6-olide) (compound 1 ), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl- 3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1 ,2-b]furan-2-one (compound 1 ) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder.; The invention also relates to tumor necrosis factor-a (TNF- a) and interleukin (IL-1 , IL-6, IL-8) inhibitory activity of the said compositions. The invention relates to inhibition of the expression of intercellular adhesion molecule 1 (ICAM-1 ), vascular-cell adhesion molecule 1 (VCAM-1 ), and E-Selectin by the said compositions. The said compositions may optionally contain at least one anti-inflammatory agent or can be used in combination with at least one anti- inflammatory agent.

This invention relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion molecule gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of vascular cell adhesion molecule genes, such as vascular cell adhesion molecule-1 (VCAM-1).

The invention relates to a medicine for curing atherosclerosis, in particular to application of oligochitosan in preparing a medicine for preventing from the formation of atherosclerosis. The application takes lipopolysaccharide (lipopolysaccharide) and humanized gene recombinant tumor necrosis factor-alpha (TNF-alpha) as an induction factor, and takes human umbilical vein endothelial cell as a research object, thereby having the following results: (1) the oligochitosan can obviously restrain the expressions of IL-8, IL-6 and relevant inflammatory factors in the lipopolysaccharide-induced human umbilical vein endothelial cell; (2) the oligochitosan can obviously restrain the expressions of membrane surface molecules VCAM-1. ICAM-1 and relevant adhesion molecules family members of the TNF-alpha-induced human umbilical vein endothelial cell; and (3) the oligochitosan can obviously restrain the adhesion between the TNF-alpha-induced human umbilical vein endothelial cell and the human mononuclear cell.

The invention belongs to the technical field of medicine, and relates to a preparation method of NF-kB decoy ODNs carried by a targeting DNA nano-self-assembly body and application thereof. NF-kB decoy ODNs carried by the targeting DNA nano-self-assembly body is composed of a DNA tetrahedron, NF-kB decoy ODNs and VCAM-1 targeting polypeptide, wherein NF-kB decoy ODNs and VCAM-1 targeting polypeptide are connected to the DNA nano-self-assembly body according to the rule of complementation base pairing. The average particle size of the DNA nano-self-assembly body is less than 10 nm. NF-KB decoy ODNs carried by the targeting polypeptide-modified DNA nano-self-assembly body improves the targeting capability of genetic drugs and the in-vitro anti-inflammatory effect of the drugs, and has no toxicity to cells and tissue.

The present disclosure relates to compositions and methods for identifying a subject at risk for traumatic brain injury. In particular, the instant disclosure is directed to identification of the levels of the proteins MMP-9 (Matrix Metallopeptidase 9), NSE (Neuron Specific Enolase) and VCAM-1 (Vascular Cell Adhesion Molecule 1) in a subject sample, and correlation of these protein levels with the presence of intracranial injury. In certain embodiments, subject age, gender and hemoglobin level are also correlated with the presence of intracranial injury.

A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.

A method for treating a VCAM-1 mediated disease comprising administering a therapeutically effective amount of a monoclonal antibody to a patient in need thereof. The monoclonal antibody specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1). The monoclonal antibody comprises(a) a light chain CDR 1 region defined by SEQ ID NO:5, a light chain CDR 2 region defined by SEQ ID NO:6, and a light chain CDR 3 region defined by SEQ ID NO:7, and (b) a heavy chain CDR 1 region defined by SEQ ID NO:8, a heavy chain CDR 2 region defined by SEQ ID NO:.9 or 11, and a heavy chain CDR 3 region defined by SEQ ID NO:10 or 12.

The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.